| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Silvia Rossi, Chiara Prosperetti, Barbara Picconi, Valentina De Chiara, Giorgia Mataluni, Giorgio Bernardi, Paolo Calabresi, Diego Centonz. Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease. Neuroscience letters. vol 410. issue 1. 2007-01-23. PMID:17070651. |
in both models, we found a significant down-regulation of glutamate transmission, suggesting that reduced synaptic excitation of the input structure of the basal ganglia represents a physiological correlate of hd. |
2007-01-23 |
2023-08-12 |
mouse |
| L Chen, K K L Yung, W H Yun. Neurotensin selectively facilitates glutamatergic transmission in globus pallidus. Neuroscience. vol 141. issue 4. 2006-12-04. PMID:16814931. |
whole-cell patch-clamp recordings were used to investigate the modulatory effects of neurotensin on glutamate and gaba transmission in this basal ganglia nucleus in rats. |
2006-12-04 |
2023-08-12 |
rat |
| Marie-Thérèse Armentero, Roberto Fancellu, Giuseppe Nappi, Placido Bramanti, Fabio Blandin. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiology of disease. vol 22. issue 1. 2006-06-01. PMID:16289868. |
prolonged blockade of nmda or mglur5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of parkinson's disease. |
2006-06-01 |
2023-08-12 |
rat |
| F Mátyás, Y Yanovsky, K Mackie, W Kelsch, U Misgeld, T F Freun. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience. vol 137. issue 1. 2006-04-05. PMID:16289348. |
the present data are consistent with a role of endocannabinoids in the control of gaba, but not glutamate, release in the basal ganglia via presynaptic cb1 receptors, but also call the attention to possible non-cb1-mediated effects of widely used cannabinoid ligands on action potential generation. |
2006-04-05 |
2023-08-12 |
rat |
| Mario van der Stelt, Susan H Fox, Michael Hill, Alan R Crossman, Stefania Petrosino, Vincenzo Di Marzo, Jonathan M Brotchi. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 19. issue 9. 2006-02-23. PMID:15894565. |
endocannabinoids and cannabinoid cb1 receptors play a role in the control of movement by modulating gaba, glutamate, and other neurotransmitters throughout the basal ganglia. |
2006-02-23 |
2023-08-12 |
monkey |
| Diane T Stephenson, Qiu Li, Carol Simmons, Mark A Connell, Martin D Meglasson, Kalpana Merchant, Marina E Embor. Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration. Neurobiology of disease. vol 20. issue 2. 2006-01-23. PMID:15882945. |
this study investigated the consequences of levodopa treatment on the expression of the 65- and 67-kda isoforms of glutamate decarboxylase (gad65 and gad67) immunoreactivity in the basal ganglia and cortex of monkeys rendered parkinsonian by systemic mptp administration. |
2006-01-23 |
2023-08-12 |
monkey |
| Ana Cabranes, Katerina Venderova, Eva de Lago, Filomena Fezza, Antonio Sánchez, Leyre Mestre, Marta Valenti, Antonio García-Merino, José Antonio Ramos, Vincenzo Di Marzo, Javier Fernández-Rui. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiology of disease. vol 20. issue 2. 2006-01-23. PMID:16242629. |
in the present study, using the same model, we explored the potential changes in several neurotransmitters in the basal ganglia that might be associated with the motor disturbances described in these rats, but we only found a small increase in glutamate contents in the globus pallidus. |
2006-01-23 |
2023-08-12 |
rat |
| P Bonsi, D Cuomo, C De Persis, D Centonze, G Bernardi, P Calabresi, A Pisan. Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 function in striatal cholinergic interneurons. Neuropharmacology. vol 49 Suppl 1. 2005-12-07. PMID:16005029. |
within basal ganglia, group i metabotropic glutamate receptor subtypes (mglur1 and 5) frequently co-localize in the same neuron. |
2005-12-07 |
2023-08-12 |
Not clear |
| P Jeffrey Conn, Giuseppe Battaglia, Michael J Marino, Ferdinando Nicolett. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nature reviews. Neuroscience. vol 6. issue 10. 2005-11-29. PMID:16276355. |
metabotropic glutamate receptors in the basal ganglia motor circuit. |
2005-11-29 |
2023-08-12 |
Not clear |
| P Jeffrey Conn, Giuseppe Battaglia, Michael J Marino, Ferdinando Nicolett. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nature reviews. Neuroscience. vol 6. issue 10. 2005-11-29. PMID:16276355. |
these advances, combined with a new understanding of the rich distribution and diverse physiological roles of metabotropic glutamate receptors in the basal ganglia, indicate that these receptors might have a key role in motor control and raise the exciting possibility that they might provide therapeutic targets for the treatment of parkinson's disease and related disorders. |
2005-11-29 |
2023-08-12 |
Not clear |
| Pershia Samadi, Laurent Grégoire, Arash Rassoulpour, Paolo Guidetti, Emanuela Izzo, Robert Schwarcz, Paul J Bédar. Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys. Movement disorders : official journal of the Movement Disorder Society. vol 20. issue 7. 2005-11-14. PMID:15954116. |
homeostatic interactions between dopamine and glutamate are central to the normal physiology of the basal ganglia. |
2005-11-14 |
2023-08-12 |
monkey |
| Yan-Qin Wang, Hui-Jing Hu, Rong Cao, Liang-Wei Che. Differential co-localization of neurokinin-3 receptor and NMDA/AMPA receptor subunits in neurons of the substantia nigra of C57/BL mice. Brain research. vol 1053. issue 1-2. 2005-10-27. PMID:16038885. |
the co-expression of nk-3r and nmda/ampa receptor subunits in the nigral neurons has provided a structural basis for functional modulation of neuronal glutamate receptors by neurokinin-3, suggesting that neurokinin peptides may be involved in modulation of neuronal properties and excitotoxicity in the substantia nigra of basal ganglia. |
2005-10-27 |
2023-08-12 |
mouse |
| S J López-Pérez, P Vergara, J P Ventura-Valenzuela, M E Ureña-Guerrero, J Segovia, C Beas-Zárat. Modification of dopaminergic markers expression in the striatum by neonatal exposure to glutamate during development. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. vol 23. issue 4. 2005-08-01. PMID:15927757. |
results indicate that an over-stimulation of the glutamatergic system by neonatal exposure to a high glutamate concentration induces a partial loss in th-positive neurons in the sn and an important reduction in dopaminergic markers expression in the striatum, suggesting that early excitotoxicity could contribute to developmental alterations in the nigrostriatal pathway, which may be associated with various disorders of the basal ganglia. |
2005-08-01 |
2023-08-12 |
rat |
| F Moroni, A Cozzi, R Carpendo, G Cipriani, O Veneroni, E Izz. Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus. Neuropharmacology. vol 48. issue 6. 2005-06-24. PMID:15829251. |
kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus. |
2005-06-24 |
2023-08-12 |
Not clear |
| Nicholas MacInnes, Marcus J Messenger, Susan Dut. Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. British journal of pharmacology. vol 141. issue 1. 2005-01-24. PMID:14597605. |
activation of group iii metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. |
2005-01-24 |
2023-08-12 |
rat |
| Penelope J Hallett, David G Standaer. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacology & therapeutics. vol 102. issue 2. 2004-12-30. PMID:15163596. |
n-methyl-d-aspartate (nmda) glutamate receptors are a class of excitatory amino acid receptors, which have several important functions in the motor circuits of the basal ganglia, and are viewed as important targets for the development of new drugs to prevent or treat parkinson's disease (pd). |
2004-12-30 |
2023-08-12 |
Not clear |
| S Robelet, C Melon, B Guillet, P Salin, L Kerkerian-Le Gof. Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. The European journal of neuroscience. vol 20. issue 5. 2004-11-09. PMID:15341597. |
chronic l-dopa treatment increases extracellular glutamate levels and glt1 expression in the basal ganglia in a rat model of parkinson's disease. |
2004-11-09 |
2023-08-12 |
rat |
| S Robelet, C Melon, B Guillet, P Salin, L Kerkerian-Le Gof. Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. The European journal of neuroscience. vol 20. issue 5. 2004-11-09. PMID:15341597. |
however, the impact of this treatment on glutamate transmission in the basal ganglia has been poorly investigated. |
2004-11-09 |
2023-08-12 |
rat |
| S Robelet, C Melon, B Guillet, P Salin, L Kerkerian-Le Gof. Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. The European journal of neuroscience. vol 20. issue 5. 2004-11-09. PMID:15341597. |
these data show that chronic l-dopa treatment leading to dyskinesias increases basal levels of glutamate function in basal ganglia. |
2004-11-09 |
2023-08-12 |
rat |
| Masahiro Nomot. [The pharmacological and rational theory for the drug development of Parkinson's disease]. Nihon rinsho. Japanese journal of clinical medicine. vol 62. issue 9. 2004-11-06. PMID:15462380. |
the basal ganglia in the brain contains glutamate, dopamine, serotonin, noradrenaline, cck, adenosine, opioid, cannabinoid, etc. |
2004-11-06 |
2023-08-12 |
Not clear |